Big Data Analytics in Urologic Oncology: A Comprehensive Review of Large-scale Database Research and Clinical...

Large-scale databases have become an essential resource in urologic oncology, enabling the generation of real-world evidence across broad and diverse patient populations. This narrative review aims to summarize the contribution of population-based cancer registries, hospital-based clinical registries, and administrative healthcare databases to the understanding and management of prostate, bladder, renal, and other genitourinary malignancies.

Over the past decade, large database studies have provided key insights into cancer epidemiology, treatment patterns, outcomes, and healthcare disparities. These data sources complement randomized clinical trials by capturing routine clinical practice at a population level. Major findings include shifts in cancer incidence and mortality, increased adoption of active surveillance in low-risk prostate cancer, and greater use of nephron-sparing approaches in renal cell carcinoma. In addition, large-scale analyses have highlighted disparities related to patient demographics, institutional volume, and access to care. They have also contributed to evaluating the real-world effectiveness and safety of established therapies, particularly in populations often underrepresented in clinical trials. Despite their strengths-particularly large sample sizes and enhanced generalizability-big data studies remain subject to important limitations, including residual confounding, coding variability, and limited availability of granular clinical and biological information. When interpreted with appropriate methodological rigor, these observational data provide valuable evidence to support clinical decision-making, inform guideline development, and identify gaps in care. Continued improvements in data quality, analytical methods, and integration with emerging technologies are expected to further strengthen the role of real-world data in advancing urologic oncology.